Costs of tumor necrosis factor blockers per treated patient with psoriatic disease using real-world drug usation data in a US managed care population - 13/02/13
Vernon F. Schabert, PhD, IMS Health, Alexandria, VA, United States; Chakkarin Burudpakdee, PharmD, IMS Health, Alexandria, VA, United States; Crystal Watson, MS, Amgen Inc, Thousand Oaks, CA, United States; David J. Harrison, PhD, Amgen Inc, Thousand Oaks, CA, United States
Le texte complet de cet article est disponible en PDF. Research funded by Immunex Corporation, a wholly owned subsidiary of Amgen Inc, and by Wyeth, which was acquired by Pfizer Inc in October 2009. Dikran Toroser (Amgen Inc) and Jonathan Latham (Pharmascribe, LLC) assisted with the preparation of this abstract. |
Vol 68 - N° 4S1
P. AB196 - avril 2013 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?